Clinical Trial Results Show Retatrutide Exceeds Zepbound and Wegovy in Weight Loss
Eli Lilly has reported outcomes from a late-stage clinical trial for its experimental obesity drug, retatrutide. The company states the drug achieved greater weight reduction compared to its current offerings, Zepbound, and Novo Nordisk's Wegovy.
The drug, retatrutide, targets three hormones involved in weight regulation: GLP-1, GIP, and glucagon. This contrasts with existing treatments like Zepbound which targets two (GLP-1 and GIP), or older GLP-1 drugs that target only one.
In the trial, participants on the highest dose of retatrutide lost an average of up to 28.7% of their body weight over more than a year of treatment. This level of weight loss, cited as comparable to bariatric surgery, significantly surpasses the results seen with current medications. For example, some participants experienced such substantial weight loss that they withdrew from the study.
Read More: California Shares Heat Risk Data for Apps
Further Benefits and Side Effects Observed
Beyond weight loss, retatrutide also demonstrated a reduction in knee arthritis pain among participants. This suggests potential broader health benefits for individuals struggling with obesity-related comorbidities.
However, the drug was not without adverse effects. More than one in five patients on the highest dose experienced dysesthesia, an unpleasant nerve sensation. Gastrointestinal issues were also noted, occurring about twice as frequently on a low dose compared to a placebo.
Market Implications and Company Stance
Eli Lilly is positioning retatrutide as a significant advancement in its obesity drug portfolio, aiming to maintain its dominant presence in a rapidly growing market. The company's executive vice president, Kenneth Custer, highlighted the drug's performance as competitive, though some observers may have anticipated even more dramatic results given the high expectations surrounding the drug.
Further studies are underway to fully assess the drug's impact on other health indicators, such as osteoarthritis and sleep apnea. Medical supervision for patients on potent weight-loss medications remains a crucial consideration due to potential risks like muscle loss and osteoporosis.
Read More: Apixaban API Market North America Leads Growth to 2034
Background
Retatrutide represents Eli Lilly's next-generation approach to tackling obesity, building on the success of its existing weight-loss medications. The company has seen substantial sales from drugs like Mounjaro and Zepbound, and retatrutide is anticipated to be a key product for sustaining this growth. The development comes as the obesity drug market continues to expand, with significant investment and competition among pharmaceutical giants.
